Administration of suxamethonium to patients with critical illness polyneuropathy may produce life-threatening hyperkalaemia. A questionnaire to assess the awareness of this problem was sent to all UK intensive care units. A clinical scenario suggestive of critical illness polyneuropathy was accompanied by a list of possible drugs used to facilitate endotracheal intubation. Most respondents (68.7%) chose suxamethonium while 20.4% avoided any muscle relaxant. This result suggests a worrying lack of appreciation of the dangers of suxamethonium use in critical illness polyneuropathy.
Hyperkalaemia in response to administration of suxamethonium is a well recognised phenomenon in certain conditions such as burns and acute denervation in spinal injury 1. Acute weakness syndromes have been recognised in critically ill patients since 1974 2 , and the term critical illness polyneuropathy (CIP) was coined in 1983 3, 4 . The life-threatening consequences of suxamethonium administration to patients with CIP were described initially in 1990 [5] [6] [7] and again more recently 8 : essentially, the result may be an almost immediate rise in serum potassium of up to 5 mmol.l -1 and resultant ventricular fibrillation or other life-threatening dysrhythmia. We carried out a questionnaire survey of intensive care units to determine the level of recognition of both CIP and, more specifically, the contraindication to suxamethonium in CIP.
METHODS
In March 1998 we sent a questionnaire addressed to the clinical director of all U.K. intensive care units as listed by the Intensive Care Society. We presented five clinical scenarios in which a patient required intubation, with a list of options from which the con-sultant was asked to choose the agent he or she would use to facilitate the procedure (Table 1 ). Our interest was in scenario four. In order to make the decision more difficult, we included a previous grade three laryngoscopy.
RESULTS
Of the 284 units surveyed 149 replied-approximately 52%, although not every response had answered each scenario ( Table 1 ). The vast majority were mixed medical and surgical ICU (133, 90%), followed by neuro ICU (9, 6%), surgical ICU (3, 2%) then cardiothoracic ICU and coronary care units (1 each, 1%). Seventy-one (48%) units had five beds or fewer, 68 (46%) had between six and ten, and eight (6%) had greater than ten. The responses to the questionnaire are shown in Table 2 , with the results for scenario four also shown graphically in Figure 1 .
In response to scenario 4, 68.7% chose suxamethonium to facilitate intubation, while 20.4% avoided muscle relaxant altogether. In response to scenario five, 54.5% chose suxamethonium, while 22.7% chose rocuronium. The size or type of unit made no difference to the responses except for neuro ICU (of nine responses, seven answered scenario 4; two chose suxamethonium, one volatile induction, one atracurium and three opted for alfentanil/ propofol; answers to other questions were similar).
DISCUSSION
While scenarios 1, 2, 3 and especially 5 are of some interest, the main purpose of this questionnaire lies in scenario 4. This is a difficult scenario and was intended to be so. Our aim was to evaluate the awareness of critical illness polyneuropathy, and in particular the dangers of suxamethonium administration in this condition. Our principal finding was that 68.7% of respondents chose to use suxamethonium when there was a high likelihood that the patient had CIP. This is a dramatic result because there is no doubt that the use of suxamethonium in patients with critical illness polyneuropathy is potentially fatal 5-8 . The patient described is at high risk of CIP because he is a long-term patient (over seven days) and has had severe sepsis, after which the incidence of CIP is approximately 70% [9] [10] [11] [12] . Although only half of these cases are symptomatic, he has failed to wean despite no obvious cardiac or respiratory cause; this is the most usual presentation of CIP 9, 10 . There are certainly other causes for failure to wean. Nevertheless CIP is a significant contributor to this problem, and it is the failure to recognise the possibility that may lead to the inappropriate use of suxamethonium. Around the time of re-intubation, hypoxia, hypotension and anaphylaxis are also potential causes of death. It is therefore likely that (even in the absence of recog-nition of the dangers of giving suxamethonium) a death will not necessarily seem particularly difficult to explain. This may lead to under-reporting of this phenomenon. Certainly, if over two thirds of consultants responding to this survey use suxamethonium in circumstances similar to these, it is difficult to believe that it is not a more common cause of death than is currently realised. Strong arguments could certainly be made for avoiding muscle relaxation on the grounds of potential intubation difficulty, and 20.4% of respondents chose these options (1 and 8) . The 68.4% who selected suxamethonium did so either in ignorance that a possible consequence is massive hyperkalaemia, or because the benefit of unequalled rapidity of offset of action in the event of failure to intubate outweighed the risks of serious hyperkalaemia. In the extreme situation of grave respiratory failure in the intensive care unit, this choice is inappropriate for two reasons: the overwhelming majority of patients can be manually ventilated; and, if the patient is to survive, failure to institute ventilation, of some variety, is simply not an option. Rocuronium in large dose has a similar speed of onset to suxamethonium 13 , and hence would appear to be the muscle relaxant of choice for facilitating intubation in this case.
There are three criticisms that could be levelled at the study. Firstly, that our intentions were not made clear. However, our aim was to ascertain which agent people would use in a normal clinical setting. To inform the doctors surveyed that our interest was in critical illness polyneuropathy would have certainly changed the result but would not, in our view, have been as accurate a reflection of normal practice. Secondly, it was not made absolutely clear in the covering letter whether we were concerned with drugs to facilitate intubation or for longer-term use. Nevertheless, the 68% using suxamethonium were clearly not considering long-term paralysis; none of the patients discussed have an indication for longterm paralysis; and the inclusion of "suxamethonium" and "volatile induction" as choices reveal, if not as clearly as one would like, our true intentions. Finally, 637 SUXAMETHONIUM AND CRITICAL ILLNESS POLYNEUROPATHY Anaesthesia and Intensive Care, Vol. 27, No. 6, December 1999 at least 10 responses mentioned that a tracheostomy would probably have already been performed by day 20. This is a valid point of view, but it is not routine practice in every unit to perform tracheostomy after a set period of time, and in most units there are patients who do not receive one despite prolonged stays. This is especially true if they are potentially weanable; many patients with CIP would be eminently weanable if not for their neuropathy. Of interest also is the choice by most respondents to use suxamethonium to intubate a patient admitted with respiratory failure secondary to Guillain-Barré syndrome (scenario 5). While there is an argument for the use of suxamethonium in the early stages of the disease, before the proliferation of acetylcholine receptors, information about the time of disease onset was not given. Indeed, the question was only included in order to raise the awareness of the possibility of hyperkalaemia in response to suxamethonium. The authors' opinions are that a rapid sequence induction using rocuronium is, in the presence of a normal airway, the best choice.
In summary, our main message is that it appears that the dangers of the combination of suxamethonium and CIP are not generally recognised at present. We therefore hope this survey will go some way to widen awareness of this avoidable and potentially fatal admixture.
